X4 Pharmaceuticals Reports Third Quarter 2022 Financial : co

Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its...

Related Keywords

United States , Boston , Massachusetts , Murray Stewart , Paula Ragan , Mark Baldry , Diego Cadavid , Development Rd Expenses , Pharmaceuticals Nasdaq , Rhythm Pharmaceuticals , Chief Executive Officer , Chief Commercial , Chief Medical Officer , Clinical Head , Biopharma Unit , Therapy Area Head , Cash Equivalents , Restricted Cash , Administrative Expenses , Nasdaq Xfor , X4 Pharmaceuticals ,